Arbutus Biopharma Corp Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price
Arbutus Biopharma Corp (ABUS) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price of 8.19 CAD/shares for the 9-month period ending 2016-09-30, per its 10-Q filed 2016-11-03.
Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice · last filed 2016-11-03
- Arbutus Biopharma Corp share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for the quarter ending 2016-03-31 was 5.94 CAD/shares.
- Arbutus Biopharma Corp share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for fiscal 2014 was 8.20 CAD/shares, a 62.51% decline from fiscal 2013.
- Arbutus Biopharma Corp share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for fiscal 2013 was 21.87 CAD/shares, a 2.82% increase from fiscal 2012.
- Arbutus Biopharma Corp share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for fiscal 2012 was 21.27 CAD/shares.
CAD/shares
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price 12 month |
|---|---|---|---|---|
| 2016-09-30 | 8.19 CAD/shares 10-Q · filed 2016-11-03 | |||
| 2016-06-30 | 5.94 CAD/shares 10-Q · filed 2016-08-04 | |||
| 2016-03-31 | 5.94 CAD/shares 10-Q · filed 2016-05-04 | |||
| 2014-12-31 | 8.20 CAD/shares 10-K · filed 2015-03-13 | |||
| 2013-12-31 | 21.87 CAD/shares 10-K · filed 2015-03-13 | |||
| 2012-12-31 | 21.27 CAD/shares 10-K · filed 2015-03-13 |
USD/shares
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price 12 month |
|---|---|---|---|---|
| 2016-09-30 | $6.24 10-Q · filed 2016-11-03 | |||
| 2016-06-30 | $4.60 10-Q · filed 2016-08-04 | |||
| 2016-03-31 | $4.58 10-Q · filed 2016-05-04 | |||
| 2014-12-31 | $7.42 10-K · filed 2015-03-13 | |||
| 2013-12-31 | $21.23 10-K · filed 2015-03-13 | |||
| 2012-12-31 | $21.29 10-K · filed 2015-03-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 |